Peripheral Neuropathic Pain Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | AlzeCure, Eli Lilly, Bayer, Eliem, SIMR Biotech, Aptinyx, Haisco Pharma

Peripheral Neuropathic Pain Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | AlzeCure, Eli Lilly, Bayer, Eliem, SIMR Biotech, Aptinyx, Haisco Pharma
Delveinsight Business Research LLP
As per DelveInsight, the Peripheral Neuropathic Pain Market is anticipated to evolve immensely in the coming years owing to the increasing incidence and prevalence of diabetes and cancer, which are leading cause of peripheral neuropathic pain in the 7MM.

Another key factor for the Peripheral Neuropathic Pain Market growth is the development of new drugs for the treatment of neuropathic and chronic pains. Several major pharma and biotech companies are focusing on clinical trials to develop drugs for the efficient treatment of neuropathic pain. 

DelveInsight’s “Peripheral Neuropathic Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral Neuropathic Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Peripheral Neuropathic Pain drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Peripheral Neuropathic Pain treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Peripheral Neuropathic Pain: An Overview

According to the International Association for the Study of Pain (IASP), neuropathic pain is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system. Neuropathic pain can result from injury to either the central or peripheral nervous system. Chemotherapy-induced neuropathy pain and diabetic peripheral neuropathy are two examples of disorders that can be associated with neuropathic pain from peripheral nerve injury.

There is no diagnostic gold standard for neuropathic pain so making a diagnosis is based on clinical judgment. The diagnostic work-up includes screening tools such as pain questionnaires and pain drawings as well as information on the history of the disease and a detailed clinical-neurological examination. A combination of characteristic painful symptoms in an area of altered sensation on bedside testing is usually enough to make a diagnosis of neuropathic pain. When doubt arises, a more detailed examination using Quantitative Sensory Testing or conventional electrophysiology can be helpful.

The primary goals of treatment for neuropathic pain are to manage the pain as much as possible and to minimize the negative side effects of the treatment. The International Association for the Study of Pain, proposed gabapentinoids, tricyclic antidepressants (TCAs), and selective serotonin–norepinephrine reuptake inhibitors (SNRI) as the first-line drugs for neuropathic pain. Lidocaine, Capsaicin, and Tramadol have been proposed as the second-line treatment, while strong opioids (Morphine and Oxycodone) and botulinum toxin-A (BTX-A) were included as third-line treatments for peripheral neuropathic pain.

Some of the key players in the Peripheral Neuropathic Pain market at the global level include Eli Lilly, Pfizer, Daichi Sankyo, WEX Pharmaceuticals Inc., Lexicon Pharmaceuticals Inc., Bayer, and AlzeCure Pharma. In a market where generic antidepressants dominate the market, market access and reimbursement approval play a major role in the successful launch of novel expensive therapies.

Peripheral Neuropathic Pain Market Key Facts

  • According to Bouhassira D (2018), the prevalence of neuropathic pain in the general population may be as high as 7 to 8%, accounting for 20 to 25% of individuals with chronic pain.

  • According to a study by Zaja̧czkowska et al., (2019) six categories of chemotherapeutic agents can be associated with the development of painful neuropathies with a global prevalence of 19–85%.

  • As per Liedgens H et al. (2016), peripheral neuropathic pain is estimated to affect 7%–8% of the population in Europe, yet some estimates have suggested that as many as 20% of adults in Europe may be affected and that close to half of those are affected on a daily basis.

  • According to a study by Mbrah A K et al. (2022), the prevalence of neuropathic pain was 14.6%. Among those with neuropathic pain, 19.7% had diabetic neuropathy, 27.3% had back and neck pain with neuropathic involvement, and 25.1% had hereditary or idiopathic neuropathy in the US population.

  • According to Hall GC et al. (2016), the prevalence of pain of predominantly neuropathic origin has been reported as 7–8% in France and UK surveys

  • It is observed that peripheral neuropathic pain affects females more as compared to males.

Peripheral Neuropathic Pain Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Peripheral Neuropathic Pain pipeline therapies. It also thoroughly assesses the Peripheral Neuropathic Pain market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Peripheral Neuropathic Pain drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Peripheral Neuropathic Pain Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Peripheral Neuropathic Pain epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Peripheral Neuropathic Pain epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Peripheral Neuropathic Pain Epidemiology, Segmented as –

  • Total Prevalent Cases of Peripheral Neuropathic Pain in the 7MM (2019–2032)

  • Diagnosed and treatable Cases of Peripheral Neuropathic Pain in the 7MM (2019–2032)

  • Type-Specific Cases of Peripheral Neuropathic Pain in the 7MM (2019–2032)

  • Gender-Specific Cases of Peripheral Neuropathic Pain in the 7MM (2019–2032)

Peripheral Neuropathic Pain Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Peripheral Neuropathic Pain market or expected to be launched during the study period. The analysis covers the Peripheral Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Peripheral Neuropathic Pain drugs based on their sale and market share.

The report also covers the Peripheral Neuropathic Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Peripheral Neuropathic Pain companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Peripheral Neuropathic Pain Market Will Evolve and Grow by 2032 @

Peripheral Neuropathic Pain Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Peripheral Neuropathic Pain. Currently, Haisco Pharmaceutical Group is leading the therapeutics market with its Peripheral Neuropathic Pain drug candidates in the most advanced stage of clinical development.

Peripheral Neuropathic Pain Companies Actively Working in the Therapeutics Market Include

  • Haisco Pharmaceutical Group

  • AlzeCure

  • Eli Lilly and Company

  • Bayer

  • Eliem Therapeutics

  • SIMR Biotech

  • Aptinyx

  • Lexicon Pharmaceuticals

And Many Others

Emerging and Marketed Peripheral Neuropathic Pain Therapies Covered in the Report Include:

  • HSK 16149: Haisco Pharmaceutical Group

  • Halneuron: WEX Pharmaceuticals Inc

  • LX9211: Lexicon Pharmaceuticals Inc

  • BAY2395840: Bayer

  • ACD440 gel (AlzeCure Pharma

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Peripheral Neuropathic Pain Competitive Intelligence Analysis

4. Peripheral Neuropathic Pain Market Overview at a Glance

5. Peripheral Neuropathic Pain Disease Background and Overview

6. Peripheral Neuropathic Pain Patient Journey

7. Peripheral Neuropathic Pain Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Peripheral Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Peripheral Neuropathic Pain Unmet Needs

10. Key Endpoints of Peripheral Neuropathic Pain Treatment

11. Peripheral Neuropathic Pain Marketed Therapies

12. Peripheral Neuropathic Pain Emerging Drugs and Latest Therapeutic Advances

13. Peripheral Neuropathic Pain Seven Major Market Analysis

14. Attribute Analysis

15. Peripheral Neuropathic Pain Market Outlook (In US, EU5, and Japan)

16. Peripheral Neuropathic Pain Companies Active in the Market

17. Peripheral Neuropathic Pain Access and Reimbursement Overview

18. KOL Views on the Peripheral Neuropathic Pain Market

19. Peripheral Neuropathic Pain Market Drivers

20. Peripheral Neuropathic Pain Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Stereotactic Surgery Devices Market

Global Stereotactic Surgery Devices Market is projected to grow at a 5.37% CAGR during the forecast period from 2023 to 2028. Some of the key companies working in the stereotactic surgery devices market include Elekta AB, Accuray Incorporated, Ion Beam Applications S.A., Mevion Medical Systems, Varian Medical Systems, Inc., Mizuho Medical Co. Ltd., Shinva Medical Instrument, Panacea Medical Technologies Pvt. Ltd., Sumitomo Heavy Industries, Ltd, Hitachi Co. Ltd, and others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States